作者
Bart Keymeulen,Evy Vandemeulebroucke,Anette G. Ziegler,Chantal Mathieu,Leonard Kaufman,G Hale,Frans Gorus,Michel Goldman,Markus Walter,Sophie Candon,Liliane Schandené,Laurent Crenier,Christophe De Block,Jean‐Marie Seigneurin,Pieter De Pauw,Denis Piérard,Ilse Weets,Peppy Rebello,Pru Bird,Eleanor Berrie,Mark R. Frewin,Herman Waldmann,Jean‐François Bach,Daniël Pipeleers,Lucienne Chatenoud
摘要
Type 1 diabetes mellitus is a T-cell–mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a phase 1 study. To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3).